John Hardy

238.5k total citations · 32 hit papers
884 papers, 93.4k citations indexed

About

John Hardy is a scholar working on Molecular Biology, Physiology and Neurology. According to data from OpenAlex, John Hardy has authored 884 papers receiving a total of 93.4k indexed citations (citations by other indexed papers that have themselves been cited), including 359 papers in Molecular Biology, 356 papers in Physiology and 287 papers in Neurology. Recurrent topics in John Hardy's work include Alzheimer's disease research and treatments (307 papers), Parkinson's Disease Mechanisms and Treatments (212 papers) and Neurological diseases and metabolism (132 papers). John Hardy is often cited by papers focused on Alzheimer's disease research and treatments (307 papers), Parkinson's Disease Mechanisms and Treatments (212 papers) and Neurological diseases and metabolism (132 papers). John Hardy collaborates with scholars based in United Kingdom, United States and Sweden. John Hardy's co-authors include Dennis J. Selkoe, Gerald A. Higgins, Andrew Singleton, David Allsop, Andrew J. Lees, Tamás Révész, Jonathan M. Schott, Henry Houlden, Chris Lane and Karen Duff and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

John Hardy

868 papers receiving 91.4k citations

Hit Papers

The Amyloid Hypothesis of Alzheimer's Disease: Progress a... 1991 2026 2002 2014 2002 1992 2016 1991 2017 2.5k 5.0k 7.5k 10.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
    2002 11.0k citations John Hardy et al. profile →
  2. Alzheimer's Disease: The Amyloid Cascade Hypothesis
    1992 5.6k citations John Hardy et al. profile →
  3. The amyloid hypothesis of Alzheimer's disease at 25 years
    2016 4.4k citations John Hardy et al. EMBO Molecular Medicine profile →
  4. Amyloid deposition as the central event in the aetiology of Alzheimer's disease
    1991 1.9k citations John Hardy et al. profile →
  5. Alzheimer's disease
    2017 1.8k citations John Hardy, Jonathan M. Schott et al. profile →
  6. Parkinson's disease
    2009 1.6k citations Andrew J. Lees, John Hardy et al. profile →
  7. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
    2000 1.2k citations John Hardy, Karen Duff et al. profile →
  8. Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP
    2001 1.2k citations John Hardy et al. profile →
  9. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
    1996 1.2k citations Karen Duff, John Hardy et al. profile →
  10. Amyloid, the presenilins and Alzheimer's disease
    1997 1.1k citations John Hardy profile →
  11. The Amyloid-β Pathway in Alzheimer’s Disease
    2021 1.1k citations John Hardy et al. profile →
  12. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes
    1998 1.1k citations John Hardy, Karen Duff et al. profile →
  13. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein
    2000 1.0k citations Karen Duff, John Hardy et al. profile →
  14. Toxic Proteins in Neurodegenerative Disease
    2002 993 citations John Hardy et al. profile →
  15. Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene
    1991 913 citations Henry Houlden, Liana Fidani et al. profile →
  16. Endoproteolysis of Presenilin 1 and Accumulation of Processed Derivatives In Vivo
    1996 863 citations John Hardy et al. profile →
  17. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
    2003 792 citations John Hardy et al. profile →
  18. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria
    2009 698 citations Thomas Gasser, Glenda M. Halliday et al. profile →
  19. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies
    2011 660 citations John Hardy, Thomas Gasser et al. profile →
  20. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal
    2009 643 citations John Hardy Journal of Neurochemistry profile →
  21. Association of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy
    1999 600 citations Irene Litvan, Henry Houlden et al. profile →
  22. Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice
    2005 540 citations John Hardy et al. profile →
  23. The Neuropathology and Neurobiology of Traumatic Brain Injury
    2012 512 citations John Hardy, Henrik Zetterberg et al. profile →
  24. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease
    2009 509 citations Janice L. Holton, Reema Paudel et al. Brain profile →
  25. APP mouse models for Alzheimer's disease preclinical studies
    2017 500 citations Hiroki Sasaguri, Per Nilsson et al. The EMBO Journal profile →
  26. Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences
    2016 484 citations Jana Vandrovcová, John Hardy et al. profile →
  27. Genomewide Association Studies and Human Disease
    2009 484 citations John Hardy, Andrew Singleton profile →
  28. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
    2010 469 citations John Hardy, Henrik Zetterberg et al. profile →
  29. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains
    2012 440 citations John Hardy et al. profile →
  30. Genetic variability in the regulation of gene expression in ten regions of the human brain
    2014 410 citations John Hardy, Mina Ryten et al. Nature Neuroscience profile →
  31. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome
    2015 376 citations John Hardy, André Strydom et al. profile →
  32. Selective vulnerability in neurodegenerative diseases
    2018 354 citations Hongjun Fu, John Hardy et al. Nature Neuroscience profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Hardy United Kingdom 132 49.9k 34.8k 22.3k 20.6k 18.0k 884 93.4k
Eliezer Masliah United States 156 47.0k 0.9× 34.2k 1.0× 33.6k 1.5× 29.4k 1.4× 23.3k 1.3× 841 104.9k
Bradley T. Hyman United States 156 60.6k 1.2× 32.6k 0.9× 14.8k 0.7× 23.1k 1.1× 21.1k 1.2× 730 114.1k
Virginia M.‐Y. Lee United States 161 48.2k 1.0× 34.2k 1.0× 43.8k 2.0× 24.0k 1.2× 19.6k 1.1× 668 97.8k
Dennis J. Selkoe United States 153 84.4k 1.7× 49.4k 1.4× 10.2k 0.5× 24.2k 1.2× 17.8k 1.0× 484 115.8k
Mark P. Mattson United States 193 53.0k 1.1× 51.4k 1.5× 9.4k 0.4× 29.0k 1.4× 18.3k 1.0× 955 128.3k
David M. Holtzman United States 166 53.8k 1.1× 27.2k 0.8× 8.5k 0.4× 15.7k 0.8× 23.7k 1.3× 580 99.8k
Dennis W. Dickson United States 153 48.5k 1.0× 25.2k 0.7× 40.0k 1.8× 16.5k 0.8× 23.9k 1.3× 1.3k 103.6k
Kaj Blennow Sweden 158 65.7k 1.3× 33.4k 1.0× 24.3k 1.1× 13.3k 0.6× 22.0k 1.2× 2.0k 122.7k
Colin L. Masters Australia 135 52.1k 1.0× 31.1k 0.9× 7.6k 0.3× 9.5k 0.5× 10.4k 0.6× 1.1k 82.7k
John Q. Trojanowski United States 193 69.9k 1.4× 46.3k 1.3× 59.9k 2.7× 31.9k 1.5× 29.4k 1.6× 1.1k 151.7k

Countries citing papers authored by John Hardy

Since Specialization
Citations

This map shows the geographic impact of John Hardy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Hardy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Hardy more than expected).

Fields of papers citing papers by John Hardy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Hardy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Hardy. The network helps show where John Hardy may publish in the future.

Co-authorship network of co-authors of John Hardy

This figure shows the co-authorship network connecting the top 25 collaborators of John Hardy. A scholar is included among the top collaborators of John Hardy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Hardy. John Hardy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hardy, John. (2025). Alzheimer's Disease: Treatment Challenges for the Future. Journal of Neurochemistry. 169(8). e70176–e70176. 2 indexed citations
2.
Graham, Andrew, Eftychia Bellou, Janet Harwood, et al.. (2025). Human longevity and Alzheimer’s disease variants act via microglia and oligodendrocyte gene networks. Brain. 148(3). 969–984. 2 indexed citations
3.
4.
Park, Jong‐Chan, Kin Y. Mok, Haeng Jun Kim, et al.. (2022). Multi‐Omics‐Based Autophagy‐Related Untypical Subtypes in Patients with Cerebral Amyloid Pathology. Advanced Science. 9(23). e2201212–e2201212. 21 indexed citations
5.
Lalli, Giovanna, Jonathan M. Schott, John Hardy, & Bart De Strooper. (2021). Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?. EMBO Molecular Medicine. 13(8). e14781–e14781. 50 indexed citations
6.
Jiang, Yuanbing, Xiaopu Zhou, Fanny C.F. Ip, et al.. (2021). Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging. Alzheimer s & Dementia. 18(1). 88–102. 105 indexed citations
7.
Xiromerisiou, Georgia, Thomas Bourinaris, Henry Houlden, et al.. (2021). SORL1 mutation in a Greek family with Parkinson's disease and dementia. Annals of Clinical and Translational Neurology. 8(10). 1961–1969. 4 indexed citations
8.
Sánchez, Juan A., Sonia García-Ruiz, Regina H. Reynolds, et al.. (2021). Modeling multifunctionality of genes with secondary gene co-expression networks in human brain provides novel disease insights. Bioinformatics. 37(18). 2905–2911. 3 indexed citations
9.
Jacobs, Benjamin M., Jonathan P. Bestwick, Cornelis Blauwendraat, et al.. (2020). Parkinson’s disease determinants, prediction and gene–environment interactions in the UK Biobank. Journal of Neurology Neurosurgery & Psychiatry. 91(10). 1046–1054. 74 indexed citations
10.
Firth, Nicholas C., Carla M. Startin, Rosalyn Hithersay, et al.. (2018). Aging related cognitive changes associated with Alzheimer's disease in Down syndrome. Annals of Clinical and Translational Neurology. 5(6). 741–751. 54 indexed citations
11.
Fu, Hongjun, John Hardy, & Karen Duff. (2018). Selective vulnerability in neurodegenerative diseases. Nature Neuroscience. 21(10). 1350–1358. 354 indexed citations breakdown →
12.
Singleton, Andrew, John Hardy, & Thomas Gasser. (2017). The Birth of the Modern Era of Parkinson's Disease Genetics. UCL Discovery (University College London). 15 indexed citations
13.
Sasaguri, Hiroki, Per Nilsson, Shoko Hashimoto, et al.. (2017). APP mouse models for Alzheimer's disease preclinical studies. The EMBO Journal. 36(17). 2473–2487. 500 indexed citations breakdown →
14.
Ling, Helen, Gábor G. Kovács, Jean Paul Vonsattel, et al.. (2016). Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain. 139(12). 3237–3252. 101 indexed citations
15.
Berg, Daniela, Ronald B. Postuma, Bastiaan R. Bloem, et al.. (2014). Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Movement Disorders. 29(4). 454–462. 341 indexed citations
16.
Hardy, John, Christopher Bull, Gerald Kotonya, & Jon Whittle. (2011). Digitally annexing desk space for software development.. International Conference on Software Engineering. 812–815. 2 indexed citations
17.
Houlden, Henry, Susanne A. Schneider, Reema Paudel, et al.. (2010). THAP1 mutations (DYT6) are an additional cause of early-onset dystonia. Neurology. 74(10). 846–850. 68 indexed citations
18.
Hardy, John, et al.. (1996). Low sulfate seawater mitigates barite scale. Oil & gas journal. 94(50). 64–67. 36 indexed citations
19.
Hardy, John, et al.. (1987). GLUTAMATE NEUROTOXICITY AND ALZHEIMERS-DISEASE. UCL Discovery (University College London). 1 indexed citations
20.
Hardy, John, et al.. (1975). Slit-scan flow system for automated cytopathology.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 19(1). 45–52. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eliezer Masliah Breakdown of academic impact, for papers by Bradley T. Hyman Breakdown of academic impact, for papers by Virginia M.‐Y. Lee Breakdown of academic impact, for papers by Dennis J. Selkoe Breakdown of academic impact, for papers by Mark P. Mattson Breakdown of academic impact, for papers by David M. Holtzman Breakdown of academic impact, for papers by Dennis W. Dickson Breakdown of academic impact, for papers by Kaj Blennow Breakdown of academic impact, for papers by Colin L. Masters Breakdown of academic impact, for papers by John Q. Trojanowski
Rankless by CCL
2026